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Abstract
Aims/hypothesis Oxidative stress is involved in the pathophysiology of insulin resistance and its progression towards type 2
diabetes. The peroxidation of n-3 polyunsaturated fatty acids produces 4-hydroxy-2-hexenal (4-HHE), a lipid aldehyde with
potent electrophilic properties able to interfere with many pathophysiological processes. The aim of the present study was to
investigate the role of 4-HHE in the development of insulin resistance.
Methods 4-HHE concentration was measured in plasma from humans and rats by GC–MS. Insulin resistance was
estimated in healthy rats after administration of 4-HHE using hyperinsulinaemic–euglycaemic clamps. In muscle
cells, glucose uptake was measured using 2-deoxy-D-glucose and signalling pathways were investigated by western
blotting. Intracellular glutathione was measured using a fluorimetric assay kit and boosted using 1,2-dithiole-3-thione
(D3T).
Results Circulating levels of 4-HHE in type 2 diabetic humans and a rat model of diabetes (obese Zucker diabetic
fatty rats), were twice those in their non-diabetic counterparts (33 vs 14 nmol/l, p < 0.001), and positively correlated
with blood glucose levels. During hyperinsulinaemic–euglycaemic clamps in rats, acute intravenous injection of 4-
HHE significantly altered whole-body insulin sensitivity and decreased glucose infusion rate (24.2 vs
9.9 mg kg−1 min−1, p < 0.001). In vitro, 4-HHE impaired insulin-stimulated glucose uptake and signalling (protein
kinase B/Akt and IRS1) in L6 muscle cells. Insulin-induced glucose uptake was reduced from 186 to
141.9 pmol mg−1 min−1 (p < 0.05). 4-HHE induced carbonylation of cell proteins and reduced glutathione concentra-
tion from 6.3 to 4.5 nmol/mg protein. Increasing intracellular glutathione pools using D3T prevented 4-HHE-induced
carbonyl stress and insulin resistance.
Conclusions/interpretation 4-HHE is produced in type 2 diabetic humans and Zucker diabetic fatty rats and blunts insulin action
in skeletal muscle. 4-HHE therefore plays a causal role in the pathophysiology of type 2 diabetes and might constitute a potential
therapeutic target to taper oxidative stress-induced insulin resistance.
Keywords 4-HHE . Insulin resistance . Lipid aldehyde .
Peroxidation . Skeletal muscle
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Introduction
Oxidative stress is involved in the pathophysiology of many
chronic diseases and in particular contributes to the develop-
ment of insulin resistance and its progression towards type 2
diabetes [1–3]. Peroxidation of cell membrane phospholipids
associated with oxidative stress produces deleterious reactive
species. Peroxidation of n-6 polyunsaturated fatty acids
(PUFA) leads to the production of 4-hydroxy-2-nonenal (4-
HNE), while 4-hydroxy-2-hexenal (4-HHE) is released during
the oxidation of n-3-PUFA [4]. These lipid aldehydes are ma-
jor by-products of lipid peroxidation of PUFA and exhibit
potent electrophilic properties allowing them to form covalent
adducts with phospholipids, proteins and nucleotides [5, 6].
Because of their relative stability and high reactivity, these
aldehydes are thought to interfere with crucial physiological
processes such as cell cycle, apoptosis or metabolic pathways
[7–9]. Importantly, the production of 4-hydroxyalkenals is
associated with hindered insulin responses: 4-HNE-adducts
accumulate in liver and pancreatic beta cells of diabetic rats
[10–12], impairs glucose-induced insulin secretion in isolated
beta cells [13] and blunts insulin action in 3T3-L1 adipocytes
and L6 muscle cells [14, 15].
Increased consumption of n-3 PUFA might be expected to
produce beneficial effects [16]; however, enhanced 4-HHE
formation in conditions associated with oxidative stress might
be harmful. For instance, consumption of oxidised n-3 PUFA
induces oxidative stress and inflammation of mice intestine
[17]. 4-HHE has, however, received little attention, despite
its similarities in structure and its reactivity with related alde-
hydes. Indeed, 4-HHE is also produced under oxidative stress
conditions, accumulates in tissues [18, 19] and is able to form
adducts on biological molecules [20, 21]. Only a handful of
studies have shown activation of stress signalling pathways by
4-HHE [22, 23] but data regarding its pathophysiological ef-
fects remains scarce. Especially, the putative role of 4-HHE in
the development of insulin resistance has not been investigat-
ed. In the present study we hypothesised that circulating levels
of 4-HHE are elevated in diabetic individuals and that 4-HHE
can impair insulin responses in skeletal muscle cells and con-
tribute to insulin resistance in vivo.
Methods
Reagents 4-HNE and 4-HHE were synthesised as previously
described [24]. Insulin (Actrapid, 100 U/ml) was from Novo
Nordisk (La Défense, France) and ECL reagent and 2-deoxy-
D-2,6-[3H]glucose were from GE Healthcare (Orsay, France).
1,2-Dithiole-3-thione (D3T) was from Interchim (Montlucon,
France). All other reagents were from Sigma-Aldrich (Saint
Quentin Fallavier, France).
Antibodies Antibodies to Ser473-Akt, total Akt, p85 and total
IRS1 (dilution 1:1000) were from Cell Signaling (Leiden, the
Netherlands). Secondary antibodies (dilution 1:10,000) were
from Sigma-Aldrich (Heidelberg, Germany). Anti-HHE-
Michael adducts antibodies were from Cosmobio (Tokyo,
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Japan). Antibodies for insulin signalling were validated using
insulin as a positive control. Anti-HHE antibody specificity
was tested against protein lysates incubated with 4-HHE or 4-
HNE.
Participants Fifteen individuals with type 2 diabetes mellitus
and 17 healthy volunteers were recruited from an ongoing
study at Hospices Civils de Lyon. The characteristics of the
participants are shown in Table 1. The study was approved by
the local ethics committee (reference D-09-17) and written
informed consent was obtained from all volunteers. After an
overnight fast, blood samples were collected, centrifuged at
1500 g for 10 min to isolate plasma and stored at −80°C.
Animal experiments All animal experiments were performed
under authorisation no. 69-266-0501 (INSA-Lyon, DDPP-SV,
Direction Départementale de la Protection des Populations -
Services Vétérinaires du Rhône) according to the guidelines
laid down by the French Ministry of Agriculture (no. 2013-
118) and the European Union Council Directive for the pro-
tection of animals (2010/63UE).
The rats used in all experiments were raised in an air-
conditioned room with a controlled environment of 21 ±
0.5°C and 60–70% humidity, under a 12 h light–dark cycle
(light on from 07:00 to 19:00 hours) with free access to food
(2016C, 12.6 kJ/g; Harlan, Gannat, France) and water. Rats
were housed together and randomised into groups on the day
of the experiment using random numbers.
Zucker diabetic fatty rats Five-week-old male lean (ZDF-
Leprfa/+/?, n = 5) and obese Zucker diabetic fatty (ZDF) rats
(ZDF-Leprfa/Crl, n = 5), a rat model of diabetes, were pur-
chased from Charles River Laboratories (L’Arbresle,
France). The characteristics of the rats are shown in Table 2.
At 15 weeks of age, rats were deeply anaesthetised with sodi-
um pentobarbital (120 mg/kg i.p.). Terminal cardiac blood
puncture was collected into a heparinised syringe and blood
was centrifuged for 2 min at 3500 g to prepare plasma, snap-
frozen in liquid nitrogen and stored at −80°C. Blood glucose
was measured with a glucometer (Accu-Check Performa;
Roche, Meylan, France) and insulin was determined using
an enzyme immunoassay (EIA) according to the manufac-
turer ’s recommendations (A05005; Bertin Pharma,
Montigny le Bretonneux, France). HbA1c was determined on
whole blood using a rat glycated haemoglobin assay kit
(80300; Crystal Chem, Zaandam, the Netherlands).
Euglycaemic–hyperinsulinaemic clamps Clamps were per-
formed in 3-month-old anaesthetised male Wistar rats
[25] purchased from Janvier (Le-Genest-Saint-Isle,
France). Rats were fasted overnight, anaesthetised with so-
dium pentobarbital (35 mg/kg i.p.; Sanofi Santé Animale,
Centravet, Lapalisse, France) and chlorpromazine
(5 mg/kg, i.p., Largactil; Sanofi-Aventis, Paris, France)
and then implanted with indwelling catheters (PE-20;
Phymep, Paris, France) in the left carotid artery and left
and right jugular veins. After catheterisation, four rats were
infused with 4-HHE (10 mg/kg, 0.1 ml) and four rats were
infused with the vehicle (DMSO, 0.1 ml) in the left jugular
vein. A standard 2 h clamp [25] was conducted using a
primed and continuous infusion of human recombinant in-
sulin (Actrapid) at a rate of 6 mU kg−1 min−1 coupled with a
variable infusion of 25% (wt/vol.) glucose to maintain
blood glucose concentration at approximately 6 mmol/l.
Blood glucose was measured every 5 min using a
glucometer (Accu-Check Performa). Plasma insulin con-
centration was determined at the end of the clamp by EIA
assay (SpiBio, Montigny le Bretonneux, France).
In vivo insulin stimulation and insulin signalling in skeletal
muscle Male Wistar rats, fasted for 7 h prior to the experi-
ments, were anaesthetised with sodium pentobarbital
(35 mg/kg i.p., Sanofi Santé Animale, Centravet) and chlor-
promazine (5 mg/kg i.p., Largactil; Sanofi-Aventis). Body
temperature was maintained at 37°C with a homeostatic blan-
ket (Harvard apparatus, les Ullis, France). A tracheotomy (PE-
240; Phymep, Paris, France) was performed to facilitate
breathing. A catheter (PE-20) was inserted into the left jugular
vein for 4-HHE infusion. Rats were either infused with 4-
HHE (10 mg/kg in 0.1 ml DMSO, n = 5) or 0.1 ml of
DMSO as a control (n = 4). One hour after infusion, rats re-
ceived an intravenous injection of either saline (154 mmol/l
NaCl) or insulin (0.75 U/kg bodyweight). Thirtyminutes after
insulin injection, rats were killed with an intravenous over-
dose of sodium pentobarbital (120 mg/kg), blood was collect-
ed by heart puncture into a heparinised syringe and gastroc-
nemius muscle was rapidly dissected out, blotted dry and
snap-frozen in liquid nitrogen.
Plasma 4-HHE and 4-HNE measurement Five hundred
microlitres of plasma were used to measure 4-HHE and 4-
HNE by GC–MS as previously described [26].
Cell culture Rat L6 muscle cells were obtained from the
American Type Culture Collection (LC/GC, Molsheim,
France) and grown as described previously [15]. Cells were
starved of serum for 4 h before treatments, which were per-
formed in serum-free Minimum Essential Medium Eagle
Alpha Modification (Sigma-Aldrich, Saint Quentin Fallavier,
France). Viability and cell death were determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction (Cell Proliferation Kit I; Roche), lactate de-
hydrogenase release (In vitro toxicology assay kit; Sigma-
Aldrich) and caspase 3 activity (Caspase 3 Assay Kit;
Sigma-Aldrich). Mycoplasma contamination was regularly
tested by PCR.
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2-Deoxy-D-[3H]glucose uptake Cells were treated with 4-HHE
and incubated for 20 min with 100 nmol/l insulin or 20 μmol/l
cytochalasin B. Glucose uptake was initiated by the addition
of 2-deoxy-D-[3H]glucose (747 GBq/mmol) to a final concen-
tration of 0.1 mmol/l for 5 min at 37°C. Uptake was terminat-
ed by three washes in ice-cold PBS and solubilisation in 0.1%
(wt/vol.) SDS. Tritium was detected by liquid scintillation
counting and results normalised by protein concentrationmea-
sured using the Bradford assay. Non-specific uptake measured
in presence of cytochalasin B was subtracted from each
determination.
Spectrophotometric 2,4-dinitrophenylhydrazine assay
Carbonyl groups on proteins were determined using 2,4-
dinitrophenylhydrazine (DNPH) as previously described
[27]. Carbonyl content was determined from the absorbance
at a wavelength of 370 nm using a molar absorption coeffi-
cient of 22,000 l mol−1 cm−1 and normalised to the protein
concentration measured at 280 nm.
Protein extraction, immunoprecipitation and immunoblot-
ting After incubation with 4-HHE, cells were washed with
PBS and proteins were extracted as described previously
[15]. For IRS1/p85 detection, whole-cell lysates were
immunoprecipitated using antibodies against IRS1. Proteins
were boiled in Laemmli buffer, separated by SDS-PAGE and
transferred onto nitrocellulose membrane. For dot blotting,
20 μg of proteins from whole-cell lysate were loaded directly
onto the nitrocellulose membrane. Following saturation with
5% (wt/vol.) BSA, membranes were probed with antibodies
and processed for chemiluminescence (ECL plus; GE
Healthcare, Coutaboeuf, France). Quantification was per-
formed using the ImageJ software (National Institutes of
Health, Bethesda, USA).
Immunofluorescence L6 cells grown on coverslips were incu-
bated with 4-HHE, fixed for 30 min with 3% (wt/vol.) para-
formaldehyde and quenchedwith 50mmol/l NH4Cl for 5 min.
After PBS washing, cells were permeabilised with 50 μg/ml
digitonin for 10 min and blocked with 0.1% (wt/vol.) BSA for
30 min. The cells were incubated with the first antibodies and
then washed and labelled with fluorescent secondary antibod-
ies. The stained cells mounted in Mowiol (Sigma Aldrich,
Saint Quentin Fallavier, France) were examined under a
Zeiss LSM 510 confocal microscope (Zeiss, Marly le Roy,
France) equipped with 63W oil objective and fluorescence
was quantified using Image J software v1.56.
Glutathione assay Reduced glutathione (GSH) was measured
using a commercially available kit from BioVision
(Clinisciences, Montrouge, France) and normalised to the pro-
tein concentration measured using the Bradford assay.
Statistics Experimenters were not blind to group assignment.
Data were analysed using Graphpad Prism (Graphpad
Software, La Jolla, CA, USA) and presented as means ±
SEM. Results were compared by one-way or two-way
ANOVA followed when appropriate by post hoc Fisher
Table 1 Demographic and
clinical characteristics of
participants
Characteristic Healthy individuals Type 2 diabetes p value
Sex, n male/n female 15/2 14/1 0.738
Age, years 51 (41–57) 66 (55–74) <0.001
BMI, kg/m2 23.9 ± 2.9 30.8 ± 5.0 <0.001
Fasting plasma glucose, mmol/l 5.1 (4.6–5.4) 9.4 (7.5–12.7) <0.001
HbA1c, mmol/mol 34.4 (33.3–36.6) 70.5 (60.7–77.0) <0.001
HbA1c, % 5.3 (5.2–5.5) 8.6 (7.7–9.2) <0.001
Systolic blood pressure, mmHg 129 ± 13 131 ± 21 0.770
Diastolic blood pressure, mmHg 81 ± 11 72 ± 11 0.045
Total cholesterol, mmol/l 5.81 ± 1.65 3.94 ± 1.11 0.012
HDL-cholesterol, mmol/l 1.22 ± 0.31 0.88 ± 0.25 0.009
Triacylglycerols, mmol/l 1.19 ± 0.60 2.22 ± 0.87 0.003
Values are presented as mean±SD or as median (interquartile range) if data were not normally distributed
Statistical significance was determined by Student’s t test or Mann–Whitney U test. Categorical data (i.e. sex)
were compared using Fisher’s exact test. p < 0.05 was considered significant
Table 2 Characteristics of 15-week-old lean and obese ZDF rats
Characteristic Lean Obese
Body weight, g 385 ± 7 729 ± 54***
Fasting blood glucose, mmol/l 4.44 ± 0.28 25.50 ± 1.33***
Fasting insulin, pmol/l 168 ± 26 427 ± 52***
HbA1c (mmol/mol) 28.3 ± 1.7 73.9 ± 2.3***
HbA1c (%) 4.74 ± 0.28 8.91 ± 0.28***
Values are mean±SEM, n = 5
***p < 0.001 vs lean (Student’s t test)
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PLSD tests. Simple comparisons were performed with
Student’s t test usingWelch’s correction for variance in homo-
geneity whenever needed. Differences were considered signif-
icant at the p < 0.05 level.
Results
4-HHE accumulates in plasma from individuals with type 2
diabetes The concentration of free 4-HHE, measured
using GC–MS, was significantly increased in plasma
from individuals with type 2 diabetes compared with
plasma from healthy volunteers (33 vs 14 nmol/l,
p < 0.001) (Fig. 1a). Diabetic individuals also exhibited
a significant increase (sevenfold) in 4-HHE Michael ad-
ducts on plasma proteins (Fig. 1b). In contrast, 4-HNE
levels did not differ between diabetic and healthy indi-
viduals; neither did the plasma concentrations of n-3 and
n-6 fatty acids (data not shown). Normalisation of 4-
HHE and 4-HNE to the concentration of their respective
n-3 and n-6 precursors showed that one out of 20,000 n-
3 PUFA were oxidised in the form of 4-HHE, while only
one out of 100,000 n-6 PUFA were oxidised in the form
of 4-HNE (Fig. 1c). Significant correlations with 4-HHE
plasma concentrations were found for blood glucose
levels (Fig. 1d) and for BMI, HbA1c, triacylglycerol
and HDL-cholesterol (Table 3).
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Fig. 1 Plasma levels of 4-HHE
are increased in type 2 diabetes.
(a) Concentration of 4-HHE and
4-HNE in plasma from
individuals with type 2 diabetes or
from healthy volunteers,
measured using GC–MS. (b) 4-
HHE adducts on plasma proteins,
measured by dot blot using anti-4-
HHE Michael adduct antibody.
AU, arbitrary units. (c)
Normalisation of 4-HHE and 4-
HNE to the concentration of n-6
PUFA and n-3 PUFA,
respectively, measured byGC. (d)
Correlation between plasma 4-
HHE levels and blood glucose
levels. (e) Concentration of 4-
HHE and 4-HNE in plasma from
obese ZDF rats (n = 5) or lean
ZDF rats (n = 5), measured by
GC–MS. (f) Blood glucose levels
in the lean and obese ZDF rats
measured using a glucometer.
Data are means or means±SEM.
***p < 0.001 (two-way
ANOVA). White circles, healthy
volunteers (control); black
squares, individuals with type 2
diabetes (T2D); white triangles,
lean ZDF rats; black triangles,
obese ZDF rats
Table 3 Univariate correlations with 4-HHE plasma concentrations
in participants
Variable r p value
Age, years 0.420 0.017
BMI, kg/m2 0.692 <0.001
SBP, mmHg 0.014 0.942
DBP, mmHg −0.300 0.113
Fasting glucose, mmol/l 0.695 <0.001
HbA1c (mmol/mol) 0.750 <0.001
Triacylglycerol, mmol/l 0.588 0.003
Total cholesterol, mmol/l −0.302 0.184
HDL-cholesterol, mmol/l −0.549 0.007
4-HNE, nmol/l 0.267 0.139
Total n-3 PUFA, mmol/l 0.643 <0.001
4-HHE Michael adducts, AU 0.805 <0.001
AU, arbitrary units; DBP, diastolic BP; SBP, systolic BP
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4-HHE and 4-HNE in plasma from ZDF rats A plasma concen-
tration of 40 nmol/l of free 4-HHE was measured in lean ZDF
rats and a fourfold increase (p < 0.001) was observed in obese
ZDF rats (Fig. 1e). The plasma concentration of 4-HNE was
increased by 80% in ZDF rats (p < 0.001). As in humans, a
significant correlation was found between the concentration of
4-HHE and blood glucose levels (Fig. 1f).
4-HHE infusion induces insulin resistance in rats To demon-
strate that 4-HHE plays a causal role in insulin resistance,
insulin sensitivity was measured using euglycaemic–
hyperinsulinaemic clamps in Wistar rats given an intravenous
bolus of 4-HHE (10 mg/kg). The injection induced a transient
increase in plasma concentration of 4-HHE, which reached
140 nmol/l 30 min after injection, while plasma 4-HNE con-
centration remained unaffected (Fig. 2a). The clamp was ap-
plied at a blood glucose level of approximately 6 mmol/l (Fig.
2b,c). The glucose infusion rate necessary to maintain
euglycaemia was significantly lower in the 4-HHE infused
rats than in the DMSO-infused rats (Fig. 2d,e), indicating
whole-body insulin resistance. In another set of experiments,
rats were infused with 4-HHE for 2 h and then received a
single injection of insulin for 20 min. Under these conditions,
the infusion of 4-HHE prevented the decreased in blood glu-
cose level induced by insulin (Fig. 2f) and abolished insulin-
induced phosphorylation of Akt in skeletal muscle (Fig. 2g,h).
Impaired insulin-stimulated glucose uptake in response to 4-
HHE In lean animals, 80–90% of infused glucose is taken up
by skeletal muscle [28] so the clamp technique primarily re-
flects skeletal muscle insulin sensitivity. We therefore went on
to characterise 4-HHE-induced insulin resistance in skeletal
muscle cells. In rat L6 cells, 4-HHE completely blunted
insulin-induced 2-deoxy-D-[3H]glucose uptake (Fig. 3a), with
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Fig. 2 4-HHE infusion induces insulin resistance in rats.
Euglycaemic–hyperinsulinaemic clampswere performed in anaesthetised
Wistar rats infused with 4-HHE (10 mg/kg i.v.) or vehicle (DMSO) as
described in Methods. (a) 4-HHE (black squares) and 4-HNE (grey tri-
angles) concentration in 4-HHE-infused rats, measured in plasma over the
2 h of the clamp experiment. Results are means±SEM, n = 4.
***p < 0.001 vs time zero. (b) Blood glucose was monitored every
5 min using a glucometer and glucose infusion rate was adjusted accord-
ingly. (c, d) Mean blood glucose (c) and glucose infusion rate (d) during
the second hour of clamp. (e) In a separate experiment, rats were injected
with 4-HHE (n = 5) or DMSO (n = 4) and after 2 h stimulated with insulin
for 20 min; during euglycaemic–hyperinsulinaemic clamp, glucose infu-
sion rate was adjusted accordingly over 2 h. (f) Blood glucose levels were
measured with a glucometer. (g, h) Representative western blot (g) and
quantification (h) of insulin-induced phosphorylation of Akt following 4-
HHE and insulin injections. Data are means±SEM, n = 4. *p < 0.05,
**p < 0.01 and ***p < 0.001 for indicated comparisons or vs DMSO;
†p < 0.05 vs no insulin (d–f, h). Black squares and bars, rats infused with
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maximal inhibition observed starting at 10 μmol/l (Fig. 3b),
lower than the concentration of 4-HNE previously reported to
impair insulin response in adipocytes and muscle cells [14,
15]. Insulin-induced glucose uptake was similarly blunted in
L6 cells exposed to 4-HNE, but with a maximal inhibition
obtained at a concentration of 50 μmol/l. Significant inhibi-
tion of insulin-induced glucose uptake by 4-HHE was ob-
served from 10 min until 4 h of treatment (Fig. 3c). In cells
treated for 30 min with up to 100 μmol/l 4-HHE, MTT reduc-
tion, lactate dehydrogenase (LDH) release and caspase-3 ac-
tivity remained unaffected, demonstrating no deleterious ef-
fects on cell viability at times and concentrations used
(Table 4).
Impaired insulin signalling induced by 4-HHE in rat L6 muscle
cells The insulin signalling cascade leading to glucose uptake
can be affected at various stages: GLUT4 translocation; pro-
tein kinase B (PKB)/Akt and/or upstream at the insulin recep-
tor and IRS. In response to 4-HHE or 4-HNE, insulin-induced
phosphorylation of PKB/Akt was reduced by 50% (Fig. 4a).
4-HHE was effective at inhibiting insulin-induced Akt phos-
phorylation at concentrations ranging from 10 to 100 μmol/l
(Fig. 4b). Similarly, exposure to 4-HHE significantly impaired
insulin-induced IRS1 phosphorylation (Fig. 4c), in parallel
with a marked reduction in the level of p85 protein co-
immunoprecipitated with IRS1 (Fig. 4d).
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Fig. 3 4-HHE impairs insulin-induced glucose uptake. Rat L6 muscle
cells were treated with 4-HHE or 4-HNE and then stimulated with
100 nmol/l insulin for 20 min. 2-Deoxy-D-[3H]glucose uptake was mea-
sured as described in the Methods. (a) Glucose uptake in L6 muscle cells
treated for 60 min with 50 μmol/l 4-HHE or 4-HNE. Data are means
±SEM, n = 5. *p < 0.05 for indicated comparisons (two-way ANOVA
for insulin vs aldehydes). (b) Glucose uptake in L6 cells treated for
30 min with increasing concentrations of 4-HHE. Data are means
±SEM, n = 5. *p < 0.05 vs 0 μmol/l 4-HHE + 100 nmol/l insulin (two-
way ANOVA). (c) Time course of insulin-stimulated glucose uptake in
L6 cells in response to 10 μmol/l 4-HHE. Data are means±SEM, n = 5.
*p < 0.05 vs 0 min (one-way ANOVA)
Table 4 Effect of 4-HHE and
4-HNE on rat L6 muscle cell
viability
Aldehyde
concentration
Cell viability
(% of control)
LDH activity
(% of total)
Caspase 3 activity
(% of control)
4-HHE
10 μmol/l 108 ± 2 0.9 ± 0.2 116 ± 2
25 μmol/l 101 ± 3 1.5 ± 0.8 117 ± 6
50 μmol/l 107 ± 4 0.9 ± 0.2 116 ± 12
75 μmol/l 120 ± 5 1.8 ± 0.7 119 ± 14
100 μmol/l 125 ± 1 1.1 ± 0.3 121 ± 12
4-HNE
10 μmol/l 105 ± 5 2.1 ± 0.4 115 ± 16
25 μmol/l 105 ± 3 2.6 ± 0.6 122 ± 15
50 μmol/l 108 ± 5 2.4 ± 0.9 116 ± 13
75 μmol/l 109 ± 3 2.4 ± 0.9 119 ± 19
100 μmol/l 106 ± 2 4.1 ± 1.3 140 ± 20
Data are means±SEM from four independent experiments
L6 muscle cells were treated for 30 min with increasing doses of 4-HHE or 4-HNE in serum-free conditions. Cell
viability was measured by MTT assay and expressed as a percentage of untreated control. LDH activity in the
supernatant fraction was expressed as a percentage of themaximal level of LDH activity determined after total cell
lysis. Caspase-3 activity was expressed as a percentage of the specific activity present in vehicle-treated cells
No significant effects were found
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4-HHE generates protein adducts in rat L6 muscle cellsMany
deleterious effects of aldehydes have been attributed to their
ability to form covalent adducts on biomolecules [5]. Indeed,
incubation of L6 muscle cells for 30 min with 4-HHE resulted
in a dose-dependent increase in carbonyl content (Fig. 5a) and
increased formation of 4-HHE Michael adducts on proteins
(Fig. 5b). Western blot analysis revealed the presence of 4-
HHE adducts on many proteins from 30 to 100 kDa (Fig. 5c)
and confocal microscopy showed that the formation of ad-
ducts was diffuse in the cell cytoplasm but was excluded from
the nuclei (Fig. 5d) without any specific co-localisation with
actin cytoskeleton or the Golgi apparatus (data not shown).
These data demonstrate that 10 μmol/l 4-HHE is sufficient to
induce carbonylation of cytoplasmic proteins in muscle cells.
Elevation of glutathione pools reverses 4-HHE-impaired glu-
cose uptake Reduced glutathione (GSH) is one of the major
aldehyde detoxification mechanisms [29]. Treatment with in-
creasing concentrations of 4-HHE indeed resulted in a sharp
dose-dependent decrease in GSH content in rat L6 muscle
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cells (Fig. 6a). This decrease was reversed by pre-treatment
with D3T (100 μmol/l, 24 h), which doubled the intracellular
GSH content and counteracted the decrease induced by 4-
HHE (Fig. 6b). D3T also reversed the 4-HHE-induced in-
crease in total carbonyl content (Fig. 6c) and protein adducts
in the cells (Fig. 6d). Pre-treatment with D3T increased the
basal glucose uptake and effectively prevented 4-HHE-
induced insulin resistance (Fig. 6e). Similarly, pre-treatment
of L6 muscle cells with N-acetyl-cysteine (NAC) or the scav-
enger of lipid peroxidation by-products aminoguanidine
(AGD) also attenuated Michael adduct formation (Fig. 6f)
and prevented the impaired insulin-induced glucose uptake
(Fig. 6g) induced by 4-HHE. Altogether, these data confirm
that adduct formation is a major player in 4-HHE-induced
insulin resistance.
Discussion
Diabetes is associated with increased oxidative stress in met-
abolic tissues and excessive production of reactive oxygen
species negatively affects insulin responses [2]. Oxidative
stress can impair cell function through direct attack by reactive
oxygen species and via the production of reactive oxidation
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Fig. 6 Increasing glutathione levels reverses 4-HHE-induced adduct
formation and impaired glucose uptake in muscle cells. (a) GSH was
measured in rat L6 muscle cells using a commercially available kit.
Data are means±SEM, n = 3. (b) L6 cells were pre-incubated with
100 μmol/l of D3T for 24 h and then treated with 50 μmol/l 4-HHE for
30 min. GSH was measured as described in Methods. Data are means
±SEM, n = 3. (c) After D3T pre-incubation, L6 cells were exposed to
50 μmol/l 4-HHE for 30 min. Carbonylation of proteins was assayed
using the DNPH assay. Data are means±SEM, n = 4. (d) Michael adducts
on proteins were detected with a dot blot using antibodies to 4-HHE
adducts. Data are means±SEM, n = 3. (e) After D3T pre-incubation and
4-HHE exposure, insulin-stimulated glucose uptake was measured using
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by-products. Here, we demonstrate that one of the by-products
of n-3 PUFA peroxidation, 4-HHE, is increased in plasma
during type 2 diabetes, induces insulin resistance in vivo and
impairs glucose uptake and signalling in skeletal muscle cells
in vitro.
Unlike radical oxygen species, lipid peroxidation by-
products are long-lived and may spread from their site of
production to exert their effects throughout the whole organ-
ism. Previous reports show that the plasma concentration of
free 4-HNE ranges from 70–600 nmol/l at baseline to up to 2–
10 μmol/l under pathological conditions [11, 30, 31]. In our
study, the 4-HNE plasma concentration in healthy volunteers
was 50 nmol/l and was surprisingly unchanged in individuals
with type 2 diabetes. On the contrary, 4-HHE concentration
was doubled in individuals with type 2 diabetes compared
with healthy individuals. The measurement of free 4-HHE or
4-HNE by GC does not take into account the amount of alde-
hydes bound to biomolecules. There are no commercially
available ELISA kits for 4-HHE adducts, so we used dot blots
to demonstrate that plasma proteins from individuals with type
2 diabetes exhibit higher levels of 4-HHE Michael adducts
(sevenfold increase). The accumulation of protein adducts
(carbonyls) has been reported in individuals with type 2 dia-
betes; urinary levels of acrolein adducts are increased and
significantly correlated with control of blood glucose [32]. A
previous study has reported a fivefold increase in 4-HHE
Michael adducts on phospholipids during diabetic retinopathy
[33]. Our study therefore reinforces the evidence for increased
production of aldehyde by-products and their adducted targets
during diabetes.
Daily supplementation with 800–1600 mg docosahexaenoic
acid (DHA) in healthy volunteers significantly increased
plasma free 4-HHE (from 9 to 93 nmol/l), likely resulting
from increased lipid peroxidation [34]. Interestingly, a
DHA supplement that did not significantly increase plasma
4-HHE (400 mg DHA/day) had beneficial effects on plate-
let function and induced antioxidant effects [35], more
recently confirmed in individuals with type 2 diabetes
[36]. In human volunteers who take n-3 PUFA supple-
ments, the balance between the beneficial effects of DHA
supplementation and the potential deleterious effects of its
by-products is therefore difficult to assess and might
depend on the concentration of DHA as well as the oxida-
tive environment.
Data from animal models and cell culture suggest that ox-
idative stress plays a causative role in the development of type
2 diabetes. Reactive oxygen species and their by-products can
have a negative impact on insulin sensitivity [2] and we dem-
onstrate here that 10 μmol/l 4-HHE is sufficient to impair
insulin-induced glucose uptake. In rat L6 muscle cells, im-
paired glucose uptake likely results from an alteration of
insulin-induced PKB/Akt phosphorylation on serine 473 as
well as IRS1 tyrosine phosphorylation and p85 docking.
Insulin-induced IRS1 phosphorylation can be counteracted
by serine phosphorylation conducted for instance by
mitogen-activated protein kinase [37, 38]. However, extracel-
lular signal-regulated kinase and c-Jun N-terminal kinases
were only mildly activated by 4-HHE in L6 cells (data not
shown), suggesting that these kinases do not play a major role
in the impairment of insulin signalling in this context. On the
contrary, we detected a significant accumulation of Michael
adducts in L6 muscle cells exposed to 4-HHE, suggesting that
the major effects of 4-HHE are due to protein carbonylation.
Detoxification of aldehydes in cells is fulfilled by several en-
zymes and antioxidant systems. Compared with 4-HNE, 4-
HHE is a poor substrate for aldehyde dehydrogenase 5A
[39] but is metabolised to GSH adducts more efficiently
[40], suggesting that GSH metabolism may be the major
mechanism for detoxification of 4-HHE. In our study, pre-
vention of carbonylation either by increasing glutathione
pools with D3T or by using the by-product scavenger
aminoguanidine reversed 4-HHE-induced insulin resis-
tance. This favours the notion that 4-HHE impairs insulin
signalling through the formation of covalent adducts on key
proteins and that GSH is a major means by which to prevent
its deleterious effects. In 3T3 adipocytes, 4-HNE directly
binds IRS1 and promotes its degradation [14]; however, we
did not observe any change in the total amount of PKB/Akt
and IRS1 proteins in response to 4-HHE. It is therefore
likely that 4-HHE exerts its noxious effects through adduc-
tion of proteins but not through the specific degradation of
proteins of the insulin signalling pathway.
In conclusion, we demonstrate that plasma levels of 4-HHE
are significantly increased in type 2 diabetes and that 4-HHE
can significantly impede insulin action in vitro and in vivo.
We also report that increasing the GSH pool is an efficient way
to prevent 4-HHE-induced carbonylation of cellular proteins
and impairment of insulin signalling. These data support the
idea that lipid peroxidation by-products, especially 4-HHE,
can significantly contribute to the development of type 2 dia-
betes and could represent a therapeutic target to taper insulin
resistance.
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